These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 18075464)

  • 41. Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy.
    Biolo A; Clausell N; Santos KG; Salvaro R; Ashton-Prolla P; Borges A; Rohde LE
    Am J Cardiol; 2008 Sep; 102(6):726-32. PubMed ID: 18773997
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilol.
    Khattar RS; Senior R; Soman P; van der Does R; Lahiri A
    Am Heart J; 2001 Oct; 142(4):704-13. PubMed ID: 11579363
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Carvedilol produces sustained long-term benefits: follow-up at 12 years.
    MacGregor JF; Wachter SB; Munger M; Stoddard G; Bristow MR; Gilbert EM
    Congest Heart Fail; 2009; 15(1):5-8. PubMed ID: 19187400
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy.
    Magnusson Y; Levin MC; Eggertsen R; Nyström E; Mobini R; Schaufelberger M; Andersson B
    Clin Pharmacol Ther; 2005 Sep; 78(3):221-31. PubMed ID: 16153393
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function.
    Lombardo RM; Reina C; Abrignani MG; Rizzo PA; Braschi A; De Castro S
    Am J Cardiovasc Drugs; 2006; 6(4):259-63. PubMed ID: 16913827
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early detection by the Tei index of carvedilol-induced improved left ventricular function in patients with heart failure.
    Palloshi A; Fragasso G; Silipigni C; Locatelli M; Cristell N; Pala MG; Alfieri O; Margonato A
    Am J Cardiol; 2004 Dec; 94(11):1456-9. PubMed ID: 15566927
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial.
    Petersen M; Andersen JT; Jimenez-Solem E; Broedbaek K; Afzal S; Nyegaard M; Børglum AD; Stender S; Torp-Pedersen C; Køber L; Poulsen HE
    Pharmacogenet Genomics; 2012 Oct; 22(10):709-15. PubMed ID: 22760495
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Carvedilol therapy in pediatric patients with dilated cardiomyopathy.
    Askari H; Semizel E; Bostan OM; Cil E
    Turk J Pediatr; 2009; 51(1):22-7. PubMed ID: 19378887
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients.
    Rau T; Düngen HD; Edelmann F; Waagstein F; Lainščak M; Dimković S; Apostolović S; Nešković AN; Haverkamp W; Gelbrich G; Eschenhagen T
    Clin Pharmacol Ther; 2012 Jul; 92(1):21-8. PubMed ID: 22617224
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of carvedilol on left ventricular diastolic function and chamber volumes in advanced heart failure.
    Palazzuoli A; Quatrini I; Vecchiato L; Scali C; De Paola V; Iovine F; Martini G; Nuti R
    Minerva Cardioangiol; 2005 Aug; 53(4):321-8. PubMed ID: 16177676
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effects of beta-blockers in patients with stable chronic heart failure. Predictors of left ventricular ejection fraction improvement and impact on prognosis.
    de Groote P; Delour P; Mouquet F; Lamblin N; Dagorn J; Hennebert O; Le Tourneau T; Foucher-Hossein C; Verkindère C; Bauters C
    Am Heart J; 2007 Sep; 154(3):589-95. PubMed ID: 17719311
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Significance of combined angiotensin II receptor blocker and carvedilol therapy in patients with congestive heart failure and arginine variant.
    Iwata A; Miura S; Nishikawa H; Kawamura A; Matsuo Y; Sako H; Kumagai K; Matsuo K; Saku K
    J Cardiol; 2006 Jan; 47(1):1-7. PubMed ID: 16475467
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of carvedilol on right ventricular ejection fraction and cytokines levels in patients with systolic heart failure.
    Tatli E; Kurum T; Aktoz M; Buyuklu M
    Int J Cardiol; 2008 Apr; 125(2):273-6. PubMed ID: 18053592
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Different ventricular remodelling and autonomic modulation after long-term beta-blocker treatment in hypertensive, ischaemic and idiopathic dilated cardiomyopathy.
    Malfatto G; Branzi G; Ciambellotti F; Valli P; Bizzi C; Facchini M
    J Cardiovasc Med (Hagerstown); 2007 Oct; 8(10):840-5. PubMed ID: 17885524
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy.
    Metra M; Nardi M; Giubbini R; Dei Cas L
    J Am Coll Cardiol; 1994 Dec; 24(7):1678-87. PubMed ID: 7963115
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dose Response of β-Blockers in Adrenergic Receptor Polymorphism Genotypes.
    Parikh KS; Fiuzat M; Davis G; Neely M; Blain-Nelson P; Whellan DJ; Abraham WT; Adams KF; Felker GM; Liggett SB; O'Connor CM; Bristow MR
    Circ Genom Precis Med; 2018 Aug; 11(8):e002210. PubMed ID: 30354340
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis.
    Schleman KA; Lindenfeld JA; Lowes BD; Bristow MR; Ferguson D; Wolfel EE; Abraham WT; Zisman LS
    J Card Fail; 2001 Mar; 7(1):4-12. PubMed ID: 11264544
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment.
    Kawai K; Hata K; Takaoka H; Kawai H; Yokoyama M
    Am Heart J; 2001 Jun; 141(6):925-32. PubMed ID: 11376305
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of the β-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between β adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study.
    Lee HY; Chung WJ; Jeon HK; Seo HS; Choi DJ; Jeon ES; Kim JJ; Shin JH; Kang SM; Lim SC; Baek SH
    Korean J Intern Med; 2016 Mar; 31(2):277-87. PubMed ID: 26879662
    [TBL] [Abstract][Full Text] [Related]  

  • 60. COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure.
    Greenberg BH; Mehra M; Teerlink JR; Ordronneau P; McCollum D; Gilbert EM
    Am J Cardiol; 2006 Oct; 98(7A):53L-59L. PubMed ID: 17023233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.